1,673 material Form 8-K filings that 1,260 companies we cover made with the SEC in February 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Molina Healthcare said it expects a non-cash, pre-tax impairment charge of about $93 million on certain intangible assets in the first quarter of 2026, tied to its decision to exit the Medicare Advantage Prescription Drug product for 2027. The company also amended its credit agreement with Truist Bank as administrative agent, temporarily lowering the minimum interest coverage ratio it must maintain, which gives it more room under the covenant through September 2027.
Estimated non-cash, pre-tax impairment charge of about $93 million on certain intangible assets, to be recorded in Q1 2026
Charge results from exiting the Medicare Advantage Prescription Drug product for 2027, which the company says does not fit its focus on dual eligible members in Medicare
First Amendment to Credit Agreement dated February 4, 2026, with Truist Bank as administrative agent; minimum interest coverage ratio cut from 3.00:1.00 to 1.75:1.00 through December 31, 2026, then rising to 2.75:1.00 by September 30, 2027
The charge will be excluded from adjusted net income, as defined in the fourth quarter earnings release issued February 5, 2026
Cantor Equity Partners VI, Inc. closed its initial public offering on February 6, 2026, selling 11,500,000 Class A ordinary shares at $10.00 per share for gross proceeds of $115 million, including the full exercise of the underwriters' over-allotment option. The company is a blank check company formed to effect a business combination with one or more businesses, and it has not yet identified a target in the filing. Shareholders' funds are held in a trust account and can be released only under the conditions described in the filing, including a business combination or redemption if no combination is completed within 24 months.
IPO closed February 6, 2026: 11,500,000 Class A ordinary shares at $10.00 each, including 1,500,000 from the full over-allotment option, for gross proceeds of $115 million.
Private placement of 300,000 Class A shares to sponsor Cantor EP Holdings VI, LLC at $10.00 per share, for $3 million; these shares cannot be transferred until 30 days after the initial business combination.
$115 million was placed in a trust account at J.P. Morgan Chase Bank, N.A., and will not be released until a business combination, a qualifying shareholder redemption, or liquidation if no combination is completed within 24 months.
Eaton entered into an $8 billion senior unsecured delayed draw term loan on February 6, 2026, with a December 31, 2026 maturity. The same day, the company's $3 billion revolving credit agreement was increased to $4 billion. The filing says the new term loan can be drawn in a single draw on the closing date, and that the company will pay ticking fees on the undrawn amount starting 60 days after February 6, 2026. For shareholders, this adds up to $8 billion in committed borrowing that the company may draw on, and the filing does not state the purpose of the funds.
$8 billion senior unsecured delayed draw term loan dated February 6, 2026, maturing December 31, 2026, with Citibank as administrative agent
Revolving credit commitments increased from $3 billion to $4 billion under a Commitment Increase Agreement, on terms otherwise unchanged
Ticking fees apply from 60 days after February 6, 2026 until the earlier of maturity or funding, based on Eaton's senior unsecured debt ratings from S&P and Moody's
Muzero Acquisition Corp, a blank check company, closed its initial public offering on February 2, 2026, selling 20,125,000 units at $10.00 each for gross proceeds of $201,250,000, including full exercise of the underwriters' over-allotment option. The $201,250,000 was placed in a U.S.-based trust account to be used for a future business combination, which has not yet been identified.
IPO of 20,125,000 units at $10.00 per unit closed February 2, 2026, for gross proceeds of $201,250,000
Concurrent private placement of 486,875 units raised $4,868,750, bought by the sponsor and BTIG, LLC
The $201,250,000 trust account balance is held in cash; the company has 24 months from the IPO closing to complete a business combination
Karman Holdings completed its acquisition of Seemann Composites and Materials Sciences on February 3, 2026, for $210 million in cash plus $10 million in common stock, subject to adjustments. The company also amended its credit agreement, refinancing $502.8 million of term loans at a rate 75 basis points lower and adding $265 million, for a total term loan principal of $767.8 million, which funded the deal and added working capital.
Acquisition consideration: $210 million cash and $10 million in common stock, subject to customary purchase price adjustments
Term loans refinanced at $502.8 million and increased by $265 million to $767.8 million total principal
Term loan rate reduced 75 basis points to SOFR plus 2.75%; revolver pricing cut 75 basis points at each leverage level
Company expects the acquisitions to be immediately accretive in 2026 to revenue growth, EBITDA, earnings per share and cash flow
On February 3, 2026, Capital One's Compensation Committee and independent directors approved a $40 million total pay package for Chairman and CEO Richard Fairbank for 2025 performance, and set his 2026 compensation plan. The filing also adopts an executive cash severance policy and a change of control severance plan, both effective March 1, 2026, which set limits on future executive severance terms.
2025 pay package totals $40 million: $2.5 million in RSUs granted February 4, 2025, plus a $37.5 million year-end incentive award
The $37.5 million incentive includes $24.8 million in performance shares tied to 2026 to 2028 performance, a $6.7 million deferred cash bonus, and RSUs with a $6.0 million grant date value
Cash Severance Policy, effective March 1, 2026, bars new executive severance above 2.99 times base salary plus target bonus without stockholder ratification
Liberty Energy completed a private offering of $700.0 million of 0.00% convertible senior notes due March 1, 2031, including a $70.0 million option that the initial purchasers exercised in full. The company plans to use the net proceeds of about $746.0 million to fund capped call transactions, repay debt under its July 24, 2025 credit agreement, and for general corporate purposes. The notes add debt, but they carry no regular interest and their conversion price of about $34.50 per share, with capped calls offsetting part of the potential dilution, could affect existing holders.
$700.0 million of 0.00% convertible senior notes due March 1, 2031, sold to initial purchasers; a $70.0 million option was exercised in full on February 4, 2026
Net proceeds of approximately $746.0 million, of which about $109.3 million funded the capped call transactions
Initial conversion price of about $34.50 per share, a premium of about 32.5% over the $26.04 closing price on February 3, 2026; initial capped call cap price of about $65.10
Remaining proceeds intended to repay indebtedness under the Credit Agreement dated July 24, 2025 and for general corporate purposes
On February 6, 2026, NXP B.V. and NXP Funding LLC amended and restated their revolving credit agreement with Barclays Bank PLC as administrative agent, providing $3 billion of senior unsecured revolving credit commitments. The facility matures February 6, 2031, and is guaranteed by NXP Semiconductors N.V. and NXP USA, Inc. For shareholders, the filing describes a renewed committed credit line with a 3.00 to 1.00 minimum interest coverage covenant, but it does not state whether any amount has been drawn.
Facility: $3 billion senior unsecured revolving commitments, including a $200 million letters of credit sub-facility
Maturity: February 6, 2031
Pricing: Term SOFR plus 0.75% to 1.25%, or base rate plus 0.0% to 0.25%, based on senior unsecured credit rating; commitment fee 0.065% to 0.15% on undrawn amounts
Covenant: consolidated interest coverage ratio of at least 3.00 to 1.00 at each fiscal quarter end
Mohawk Industries said Paul De Cock, its Chief Operating Officer, will also serve as interim president of the Flooring Rest of World segment, succeeding Wim Messiaen, who resigned on February 5, 2026 to pursue other interests. The filing says there will be no material change to De Cock's compensation, and it does not report any financial results or guidance, so the change is administrative in scope until a permanent successor is named.
Paul De Cock named interim president of Flooring Rest of World, effective immediately, until a permanent successor is found
Wim Messiaen resigned as segment president on February 5, 2026 to pursue other interests
De Cock, age 52, remains Chief Operating Officer, a role he has held since February 1, 2025
No material change to De Cock's compensation tied to the interim appointment
On February 6, 2026, United Airlines Holdings, Inc. issued $1,000,000,000 of 4.875% senior notes due March 1, 2029 in a public offering, guaranteed by its subsidiary United Airlines, Inc. The notes were sold under a shelf registration and an underwriting agreement dated February 3, 2026, and the filing does not state how the proceeds will be used.
Principal amount: $1,000,000,000; interest of 4.875% per year, paid semi-annually on March 1 and September 1, starting September 1, 2026
Maturity: March 1, 2029; UAL may redeem before December 1, 2028 at the greater of par or a make-whole amount, and at par plus accrued interest on or after that date
Covenants limit liens securing borrowed money or capital leases and mergers or asset transfers, subject to exceptions; holders may require repurchase at 101% of principal upon a Change of Control Triggering Event
Underwriters acting through Barclays Capital Inc. and BofA Securities, Inc.; issued under the Base Indenture dated May 7, 2013 with The Bank of New York Mellon Trust Company, N.A. as trustee
Hennessy Capital Investment Corp. VIII, a blank check company, closed its initial public offering on February 6, 2026, selling 24.15 million units at $10.00 each, including the full exercise of the underwriters' over-allotment option. The full $241.5 million of IPO proceeds was placed in a trust account, which generally stays there until a business combination is completed or shareholders redeem their shares, and the company has 24 months from closing to complete a combination.
IPO closed February 6, 2026: 24.15 million units at $10.00 per unit, for gross proceeds of $241.5 million
$241.5 million placed in a U.S. trust account administered by Odyssey; the company has 24 months from closing to complete an initial business combination
Sponsor HC VIII Sponsor LLC bought 671,000 private placement units for $6.71 million, with no underwriting discounts or commissions paid
Five directors appointed effective February 4, 2026, including Brian Bonner, Kyle Crowley, Javier Saade, Sandra Stash and Elizabeth Williams
The Trust's sponsor amended participant agreements with Jane Street Capital and Virtu Americas, allowing them to create and redeem shares in-kind, and NYSE Arca has received SEC approval for in-kind transactions for crypto-based ETPs, including this Trust. The Trust also moved its NYSE Arca listing to the Generic Listing Standards, which the exchange approved on December 16, 2025, and the sponsor says this is meant to keep the Trust on par with similar products.
Jane Street Capital, LLC and Virtu Americas LLC are the amended Authorized Participants, and the sponsor may add more in the future.
Shares can be created or redeemed in-kind as an alternative to the Trust's cash-based process, based on SEC approval for NYSE Arca-listed crypto ETPs.
NYSE Arca approved the Trust's listing under the Generic Listing Standards on December 16, 2025, after trading began under the Original Listing Standards on July 31, 2024.
A Basket is a block of 10,000 Shares, the minimum unit for creations and redemptions.
Edgewell Personal Care closed the sale of its Feminine Care segment to Essity on February 2, 2026, receiving approximately $340 million in cash, subject to post-closing adjustments. The company plans to use the net proceeds mainly to pay down its U.S. revolving credit facility, and its pro forma filing estimates a loss on disposal and goodwill impairment of $42.1 million net of tax, which the company says may differ materially from the final figure.
Closing date was February 2, 2026; the company received about $340 million in cash from Essity, subject to adjustments for inventory, indebtedness and other items.
Pro forma filing shows $140.0 million outstanding on the revolving credit facility as of September 30, 2025, assumed to be repaid with sale proceeds.
Estimated loss on disposal and goodwill impairment of $42.1 million, net of tax, based on September 30, 2025 balances; the goodwill impairment alone was $37.4 million.
Transition services agreement with Essity covers accounting, IT, quality assurance, operations, supply chain and sales for at least one year.
Agape ATP Corporation plans a 1-for-50 reverse stock split of its common stock on February 9, 2026, with shares trading on a split-adjusted basis on the Nasdaq Capital Market from February 10, 2026. Stockholders approved an amendment at the January 30, 2026 annual meeting allowing the board to carry out reverse splits, and the board chose this ratio. The split reduces the number of outstanding shares by a factor of 50, and the authorized share count is not changed.
Reverse split ratio is 1-for-50, effective February 9, 2026, per the filing and press release
Split-adjusted trading on Nasdaq begins February 10, 2026, under the unchanged symbol ATPC
Common stock receives new CUSIP number 008389306; fractional shares are rounded up to the nearest whole share
Stock option and award terms, including exercise prices and share counts, will be adjusted proportionally
Under Armour reported third-quarter fiscal 2026 revenue of $1.33 billion, down 5% from a year earlier, and a GAAP net loss of $431 million, which included a $247 million non-cash tax valuation allowance. The company also widened its fiscal 2026 GAAP operating loss outlook to about $154 million, while raising its adjusted diluted EPS outlook to $0.10 to $0.11 from $0.03 to $0.05, a non-GAAP measure that excludes charges. For shareholders, the GAAP results and outlook weakened even as the adjusted figures improved.
Revenue was $1.33 billion, down 5% from $1.40 billion; North America fell 10% to $757 million.
GAAP net loss was $431 million, or $1.01 per diluted share, including a $247 million valuation allowance on U.S. federal deferred tax assets.
Adjusted diluted EPS was $0.09, excluding a $99 million litigation reserve expense tied to an insurance carrier dispute.
Fiscal 2026 GAAP operating loss is now expected to be about $154 million, compared with the prior outlook of a $56 million to $71 million loss.
Cboe Global Markets reported record fourth-quarter 2025 net revenue of $671.1 million, up 28 percent, and diluted EPS of $2.97, up 60 percent from the prior-year quarter. The company also set 2026 guidance for mid single-digit organic total net revenue growth and adjusted operating expenses of $864 million to $879 million, which matters to shareholders as a baseline for the year ahead.
Q4 2025 net revenue $671.1 million, up 28 percent; adjusted diluted EPS $3.06, up 46 percent
Full-year 2025 diluted EPS $10.42, up 45 percent; full-year net revenue $2.4 billion, up 17 percent
2026 guidance: organic total net revenue growth 'mid single-digit'; adjusted operating expenses $864 million to $879 million
No share repurchases in Q4 2025; $614.5 million of buyback authorization remained at December 31, 2025
Immunovant reported results for the fiscal third quarter ended December 31, 2025, with a net loss of $110.6 million ($0.61 per share), compared with $111.1 million ($0.76 per share) a year earlier. Cash and cash equivalents were $994.5 million at December 31, 2025, following a December 2025 underwritten financing with institutional investors and Roivant that generated approximately $550 million in gross proceeds, which the company says extends its cash runway to the potential launch of IMVT-1402 in Graves' disease.
Q3 net loss was $110.6 million ($0.61 per share), versus $111.1 million ($0.76 per share) in the prior-year quarter.
R&D expenses rose to $98.9 million from $94.5 million, driven by IMVT-1402 trial activities, including contract manufacturing costs.
G&A expenses fell to $15.4 million from $19.8 million, mainly due to lower personnel-related expenses, market research and IT costs.
The December 2025 financing generated approximately $550 million in gross proceeds; shares outstanding were 203,316,885 at December 31, 2025.
Roivant reported a net loss attributable to Roivant Sciences Ltd. of $265.9 million, or $0.38 per share, for the quarter ended December 31, 2025, compared with net income of $169.4 million a year earlier. The prior-year result included a $327.0 million gain from discontinued operations tied to the Dermavant sale, and the loss from continuing operations rose to $313.7 million from $208.9 million, so shareholders face a larger operating loss even as the company reported positive Phase 2 brepocitinib data in cutaneous sarcoidosis.
Revenue was $2.0 million for the quarter, down from $9.0 million a year earlier
Loss from continuing operations was $0.38 per share, compared with $0.22 per share a year earlier
R&D expenses rose $23.8 million to $165.4 million; G&A rose $33.5 million to $175.1 million, including a $17.1 million headquarters impairment
Consolidated cash, cash equivalents, restricted cash and marketable securities totaled $4.5 billion as of December 31, 2025
Ubiquiti reported results for the fiscal quarter ended December 31, 2025, with revenue of $814.9 million, up 35.8% from a year earlier and 11.1% from the prior quarter. GAAP net income rose 70.8% to $233.6 million, or $3.86 per diluted share, compared with $2.26 a year earlier. The board also declared a $0.80 per share cash dividend, payable February 23, 2026, to shareholders of record on February 17, 2026.
Revenue of $814.9 million, up 35.8% year over year and 11.1% from the prior quarter
GAAP diluted EPS of $3.86 versus $2.26 a year earlier; non-GAAP diluted EPS of $3.88
GAAP gross margin of 45.9%, up from 41.2% a year earlier and down slightly from 46.0% in the prior quarter
$0.80 per share cash dividend payable February 23, 2026; record date February 17, 2026
AutoNation reported fourth-quarter 2025 revenue of $6.9 billion, down 4% from a year earlier, while diluted EPS rose 1% to $4.70. For the full year, revenue rose 3% to $27.6 billion and diluted EPS rose 1% to $17.04, while adjusted EPS climbed to $20.22 from $17.46. The results matter to shareholders because Q4 operating income and net income both fell 8%, even as the company repurchased $785 million of its stock in 2025.
Q4 2025 operating income was $313.9 million, down 8%, and net income was $172.1 million, down 8%.
Full-year 2025 adjusted diluted EPS was $20.22 versus $17.46 a year earlier; adjusted free cash flow was $1.05 billion.
Share repurchases totaled $785 million in 2025, with $968 million of authorization remaining as of February 4, 2026.
Piper Sandler reported record fourth-quarter 2025 net revenues of $666 million, up 38% from a year earlier, and full-year net revenues of $1.9 billion, up 24%. The board also declared a $5.00 special dividend and a $0.70 quarterly dividend, and approved a four-for-one forward stock split, which takes effect March 23, 2026.
Q4 2025 net revenues of $666 million, up 38% from Q4 2024; GAAP diluted EPS of $6.40
Full-year 2025 net revenues of $1.9 billion, up 24%; GAAP diluted EPS of $15.82 versus $10.24 in 2024
Special dividend of $5.00 and quarterly dividend of $0.70 per share, payable March 13, 2026 to holders of record March 3, 2026
Four-for-one forward split effective 4:30 p.m. ET March 23, 2026; split-adjusted trading begins March 24, 2026
Philip Morris International reported fourth-quarter and full-year 2025 results. Full-year reported diluted EPS was $7.26, up from $4.52 in 2024, and adjusted diluted EPS was $7.54, up 14.8%, while net revenues rose 7.3% to $40.6 billion. The company forecast 2026 reported diluted EPS of $7.87 to $8.02 and adjusted diluted EPS of $8.38 to $8.53.
Full-year 2025 reported diluted EPS of $7.26 versus $4.52 in 2024; adjusted diluted EPS of $7.54
Full-year 2025 net revenues of $40.6 billion, up 7.3% reported and 6.5% organically
2026 forecast: adjusted diluted EPS of $8.38 to $8.53, with no share repurchases assumed
Declared regular quarterly dividend of $1.47 per share, or $5.88 annualized
Virtus Investment Partners reported fourth-quarter 2025 results, with revenue down 11% from a year earlier to $208.0 million and adjusted diluted earnings per share down 13% to $6.50. GAAP diluted earnings per share rose 11% to $5.17, but the company said that reflected items such as investment gains and fair value adjustments, and assets under management fell to $159.5 billion, which matters to shareholders because lower assets generally reduce fee revenue.
Revenue of $208.0 million, down 11% from $233.5 million a year earlier and down 4% from $216.4 million in the prior quarter
GAAP diluted EPS of $5.17 versus $4.66 a year earlier; adjusted diluted EPS of $6.50 versus $7.50
Net outflows of $8.1 billion in the quarter versus $4.8 billion a year earlier; ending assets under management of $159.5 billion, down 9% year over year
Cash and cash equivalents of $386.5 million at December 31, 2025; the company repurchased 60,292 shares for $10.0 million during the quarter
Biogen reported fourth quarter 2025 revenue of $2.3 billion, down 7%, and a GAAP diluted loss of $(0.33) per share, compared with GAAP EPS of $1.83 a year earlier. For full year 2025, revenue rose 2% to $9.9 billion and non-GAAP diluted EPS was $15.28, above the company's $14.50 to $15.00 guidance range, though down 7% from $16.47. The company expects 2026 non-GAAP diluted EPS of $15.25 to $16.25 and a mid-single digit percentage revenue decline.
Q4 2025 total revenue was $2,279 million, down 7% year-over-year; non-GAAP diluted EPS was $1.99 versus $3.44 in Q4 2024.
Full year 2025 total revenue was $9.9 billion, up 2%; GAAP diluted EPS was $8.79 and non-GAAP diluted EPS was $15.28.
Full year 2026 guidance: non-GAAP diluted EPS of $15.25 to $16.25 and total revenue expected to decline by a mid-single digit percentage versus 2025.
Q4 2025 included approximately $131 million of GAAP other expense related to litigation matters.
nVent reported fourth-quarter 2025 sales of $1.1 billion, up 42%, and reported EPS from continuing operations of $0.71, compared with a loss of $(0.10) a year earlier. Full-year 2025 sales reached $3.9 billion, up 30%, and the company issued 2026 guidance for reported EPS of $3.27 to $3.42, with adjusted EPS of $4.00 to $4.15.
Q4 2025 reported EPS from continuing operations was $0.71 versus $(0.10) in Q4 2024; adjusted EPS was $0.90, up 53%
Full-year 2025 sales were $3.9 billion, up 30%, with organic growth of 13%
2026 guidance: reported sales growth of 15% to 18%; reported EPS of $3.27 to $3.42; adjusted EPS of $4.00 to $4.15
Investor Day is set for February 24, 2026 in New York, where medium-term financial targets will be shared
RXO reported a fourth-quarter 2025 GAAP net loss of $46 million, compared with $25 million a year earlier, with revenue down to $1.5 billion from $1.7 billion and adjusted EBITDA of $17 million versus $42 million. The company also closed a $450 million asset-based revolving credit facility on February 5, 2026, which replaces its prior $600 million facility, and expects first-quarter 2026 adjusted EBITDA of $5 million to $12 million.
Q4 2025 revenue was $1.5 billion versus $1.7 billion in Q4 2024; gross margin was 14.8% versus 15.5%
Q4 2025 GAAP net loss was $46 million, or $0.27 per diluted share, versus a net loss of $25 million, or $0.15 per share, a year earlier
Q4 2025 adjusted EBITDA was $17 million, down from $42 million; the GAAP loss included a $12 million goodwill impairment
Q1 2026 outlook: adjusted EBITDA of $5 million to $12 million, with Brokerage volume down 5% to 10% and gross margin of 11% to 13%
MarketAxess reported fourth-quarter and full-year 2025 results, with Q4 revenue up 3.5% to $209.4 million and full-year revenue up 4% to $846.3 million. Q4 GAAP diluted EPS of $2.51 was lifted by a notable tax reserve benefit of about $31.3 million, while EPS excluding notable items was $1.68, down 3%. The company also gave 2026 guidance for expenses excluding notable items of $530.0 million to $545.0 million and amended its $750.0 million credit agreement, extending maturity to February 2, 2029.
Q4 2025 total revenues were $209.4 million, up 3.5%; full-year 2025 revenues were $846.3 million, up 4%.
Q4 2025 GAAP diluted EPS was $2.51 versus $1.73 a year earlier; excluding notable items, diluted EPS was $1.68, down 3%.
Full-year 2025 GAAP diluted EPS was $6.64 versus $7.28 in 2024, down 9%; excluding notable items it was $7.39, up 2%.
The Credit Facility matures February 2, 2029; $220.0 million was outstanding as of the filing date.
Newell Brands reported fourth quarter and full year 2025 results on February 6, 2026. Fourth quarter net sales fell 2.7% to $1.9 billion and the GAAP net loss widened to $315 million from $54 million, including $340 million of non-cash impairment charges, while normalized diluted EPS rose to $0.18 from $0.16. The company initiated 2026 guidance calling for net sales of (1%) to 1% and normalized EPS of $0.54 to $0.60, which gives shareholders a baseline for the coming year.
Q4 2025 net sales were $1.9 billion, down 2.7%, with core sales down 4.1%.
Q4 net loss was $315 million versus $54 million a year earlier; diluted loss per share was $0.75.
Q4 normalized diluted EPS was $0.18 versus $0.16 in the prior year period.
2026 outlook: net sales (1%) to 1%, normalized EPS $0.54 to $0.60, operating cash flow $350 million to $400 million.
Proto Labs reported record fourth-quarter 2025 revenue of $136.5 million, up 12.1% year over year, and swung to net income of $6.0 million, or $0.25 per diluted share, from a net loss a year earlier. For full year 2025, revenue rose 6.4% to a record $533.1 million and diluted EPS was $0.88, but the company guided to 6% to 8% revenue growth for 2026, with Q1 2026 revenue expected between $130.0 million and $138.0 million.
Q4 2025 revenue was $136.5 million, up 12.1%; CNC Machining revenue rose 25.0%.
Q4 2025 diluted EPS was $0.25, versus a loss of $0.02 per share in Q4 2024.
Full year 2025 revenue was $533.1 million, up 6.4%; diluted EPS was $0.88, versus $0.66 in 2024.
2026 outlook: revenue growth of 6% to 8% for fiscal 2026; Q1 2026 revenue of $130.0 million to $138.0 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.